Stratipath is a brand that is on a mission to provide every patient with the right treatment at the right time. They bring together a diverse team of clinicians, researchers, AI scientists, developers, and industry specialists to develop novel solutions driven by state-of-the-art machine and deep learning methods. Their goal is to minimize over- and undertreatment, as well as reduce healthcare costs, benefiting all of society.

Stratipath offers a first-in-class solution for prognostic risk stratification of breast cancer, providing an alternative to expensive and time-consuming molecular assays. They have strong partnerships for commercial rollout, distribution, and optimal clinical workflow. With their SaaS solution integrated with leading digital pathology solutions, Stratipath is actively implementing their solutions in healthcare settings, including oncology clinics and pathology labs.

Their AI platform enables rapid development, validation, and deployment of AI-based precision diagnostics, supported by clinical evidence published in high-impact journals. Stratipath's vision is to enable precision medicine and provide the right treatment for every patient. By offering accelerated patient stratification and reducing diagnostic errors, their solutions contribute to a greater equality of care for all patients.

Ultimately, Stratipath aims to create sustainable healthcare by providing fast, accessible, and cost-effective precision diagnostics